Integra LifeSciences taps debt market for $600M term loan
What's the deal? Integra LifeSciences has launched a $600 million senior secured Term Loan B, the medical technology company said on October 2, 2026. The post-IPO debt deal marks a sizeable addition to the company's capital structure.
By the numbers: At $600 million, the financing ranks around the midpoint of comparable raises, landing in roughly the 52nd percentile by amount.
The signal: Term Loan B facilities give established companies long-dated, flexible financing without tapping equity markets. For a listed medtech firm like Integra, the move signals a preference to fund operations and strategy through debt while keeping existing shareholders undiluted.
Read more: marketscreener.com
Image credit: phil41dean
